GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (NAS:RARE) » Definitions » Shiller PE Ratio

Ultragenyx Pharmaceutical (Ultragenyx Pharmaceutical) Shiller PE Ratio : (As of May. 19, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Ultragenyx Pharmaceutical Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ultragenyx Pharmaceutical Shiller PE Ratio Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Shiller PE Ratio Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ultragenyx Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ultragenyx Pharmaceutical's Shiller PE Ratio

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultragenyx Pharmaceutical's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's Shiller PE Ratio falls into.



Ultragenyx Pharmaceutical Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Ultragenyx Pharmaceutical's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Ultragenyx Pharmaceutical's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-2.03/131.7762*131.7762
=-2.030

Current CPI (Mar. 2024) = 131.7762.

Ultragenyx Pharmaceutical Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.450 100.560 -0.590
201409 -0.500 100.428 -0.656
201412 -0.520 99.070 -0.692
201503 -0.630 99.621 -0.833
201506 -0.830 100.684 -1.086
201509 -1.030 100.392 -1.352
201512 -1.450 99.792 -1.915
201603 -1.350 100.470 -1.771
201606 -1.460 101.688 -1.892
201609 -1.640 101.861 -2.122
201612 -1.750 101.863 -2.264
201703 -1.630 102.862 -2.088
201706 -1.720 103.349 -2.193
201709 -1.870 104.136 -2.366
201712 -1.890 104.011 -2.395
201803 0.620 105.290 0.776
201806 -1.060 106.317 -1.314
201809 -1.740 106.507 -2.153
201812 -1.730 105.998 -2.151
201903 -1.820 107.251 -2.236
201906 -1.720 108.070 -2.097
201909 -1.960 108.329 -2.384
201912 -1.620 108.420 -1.969
202003 -2.050 108.902 -2.481
202006 0.410 108.767 0.497
202009 -1.130 109.815 -1.356
202012 -0.370 109.897 -0.444
202103 -2.030 111.754 -2.394
202106 -1.810 114.631 -2.081
202109 -1.080 115.734 -1.230
202112 -1.790 117.630 -2.005
202203 -2.190 121.301 -2.379
202206 -2.260 125.017 -2.382
202209 -3.500 125.227 -3.683
202212 -2.160 125.222 -2.273
202303 -2.330 127.348 -2.411
202306 -2.250 128.729 -2.303
202309 -2.230 129.860 -2.263
202312 -1.520 129.419 -1.548
202403 -2.030 131.776 -2.030

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ultragenyx Pharmaceutical  (NAS:RARE) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Ultragenyx Pharmaceutical Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultragenyx Pharmaceutical (Ultragenyx Pharmaceutical) Business Description

Traded in Other Exchanges
Address
60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Executives
Emil D Kakkis director, 10 percent owner, officer: President & CEO C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Thomas Richard Kassberg officer: CBO & Senior Vice President C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Howard Horn officer: Chief Financial Officer C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Theodore Alan Huizenga officer: Controller and PAO C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Erik Harris officer: EVP & Chief Commercial Officer 60 LEVERONI COURT, NOVATO CA 94949
Sanders Corazon (corsee) D. director C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
John Richard Pinion officer: See Remarks C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Karah Herdman Parschauer officer: EVP and General Counsel 60 LEVERONI COURT, NOVATO CA 94949
Eric Crombez officer: EVP and Chief Medical Officer C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Dennis Karl Huang officer: SVP and Chief Tech Ops Officer C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Camille L Bedrosian officer: EVP and Chief Medical Officer C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Mardi Dier officer: CFO & Executive Vice President C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Amrit Ray director 60 LEVERONI COURT, NOVATO CA 94949
William Aliski director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Shalini Sharp officer: CFO & Senior Vice President C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949